Clinical trials
Lung Fibrosis Interstitial clinical trials
Below are recruiting lung fibrosis interstitial clinical trials, each written for real people, not researchers. We’re tracking 80 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05392881Recruiting
Lung disease biobank for adults followed at a university clinic
This study collects and stores samples and health information from adults being followed for interstitial lung disease or certain rare lung conditions. The goal is to help researchers study these diseases over time and improve future care.
Kansas City, KansasAges 18 years+ - NCT04930289Enrolling by invitation
Lung transplant registry for better donor lung preservation
This study builds a worldwide database to track and improve how donor lungs are preserved before transplant. Your information may help doctors choose and manage donor lungs more effectively.
Phoenix, ArizonaAges Any age - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT04896138Enrolling by invitation
Natural history study for lung scarring patients
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
Charlottesville, VirginiaAges 18 years+ - NCT04016181Enrolling by invitation
Study to categorize lung fibrosis types at a clinic
This study enrolls people who have interstitial lung disease and are seen at the Edinburgh lung fibrosis clinic. It aims to sort different underlying “types” of lung fibrosis so doctors can better understand and potentially guide care.
Ages 18–99 - NCT03800017Recruiting
Muscle strength and exercise function in lung scarring
This study looks at how well skeletal (muscle) function supports exercise in people with interstitial lung diseases (including idiopathic pulmonary fibrosis). It may help better understand fitness and breathing limits, which can guide rehabilitation choices and future care.
Vancouver, British ColumbiaAges 40–80 - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Birmingham, AlabamaAges 21 years+ - NCT00470327Recruiting
Study of how interstitial lung disease naturally changes
This study looks at how interstitial lung disease (lung scarring) typically progresses over time. It may help researchers understand what to expect and what changes to watch for.
Chicago, IllinoisAges 18 years+ - NCT07761377Recruiting
Using AI to spot lung scarring on CT scans
This study tests whether an AI tool can correctly find lung scarring (pulmonary fibrosis) on CT scans as well as doctors do. The results could lead to faster, more consistent detection of this condition.
TaichungAges 20 years+ - NCT01776398Recruiting
Donating breath, blood, and urine samples for lung research
This study collects airway samples (usually during a bronchoscopy), plus blood and/or urine, to help researchers study lung conditions. It may help advance understanding of lung disease and related biology, but it is not a treatment trial.
New York, New YorkAges 18 years+ - NCT05417776RecruitingPhase 2
PET scan test for early lung scarring
This trial uses a special PET/MRI scan to look for early signs of lung scarring and inflammation using a “collagen-targeting” tracer. It may help doctors better identify early interstitial lung disease (IL D) and track it over time.
Boston, MassachusettsAges 40 years+ - NCT04299945Recruiting
Beetroot juice to boost exercise in fibrotic lung disease
This trial tests whether drinking beetroot juice can improve exercise performance in people with fibrotic interstitial lung disease (scarring in the lungs). It may help your body use oxygen better during activity if you meet the study’s safety and lung-function requirements.
Vancouver, British ColumbiaAges 19 years+ - NCT07269262Recruiting
Support program for PPF patients and their caregivers
This study tests a support program for people with progressive pulmonary fibrosis and their caregivers. It focuses on helping both the patient and the person who helps care for them.
Charleston, South CarolinaAges 18 years+ - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Birmingham, AlabamaAges 18 years+ - NCT06182748Recruiting
Physical activity and lung scarring
This study tests if a supervised exercise program, 3 times a week, helps people with lung scarring (fibrosing interstitial lung disease). It may improve your breathing and quality of life.
Bobigny, Seine Saint DenisAges 18 years+ - NCT06440746RecruitingPhase 2/Phase 3
Testing olokizumab for progressive lung scarring diseases
This trial tests a drug called olokizumab to see if it can slow down worsening lung scarring (fibrosis) in people with certain types of progressive interstitial lung diseases. It's for patients whose lung function has declined despite current treatments.
BarnaulAges 18 years+ - NCT07319598RecruitingPhase 4
Tetrandrine tablets for connective tissue disease-related lung disease
This study tests if tetrandrine tablets can help people with lung disease caused by connective tissue disorders. It is for adults 18-80 who have stable treatment and meet specific health criteria.
BeijingAges 18–80 - NCT05785065RecruitingPhase 2
Mycophenolate for early lung scarring in systemic sclerosis
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
Montreal, QuebecAges 18 years+ - NCT07457463Recruiting
Pulmonary fibrosis self-management program
This study tests a learning and self-management program for people with pulmonary fibrosis. It helps you better understand and manage your lung condition.
BernAges 18 years+ - NCT04624490RecruitingPhase 1
Lung function MRI using a special gas in volunteers
This Phase 1 study tests a lung scan that uses a special gas and MRI to measure how well your lungs work. It includes healthy volunteers and people with lung disease to see how well the scan works and how safe it is.
Kansas City, KansasAges 3 years+ - NCT06615492Recruiting
Lung transplant study: comparing two ECMO methods
This study compares two ways of using a heart-lung machine (ECMO) during lung transplant surgery. The goal is to see if using ECMO only when needed works as well as using it for everyone. This could help reduce risks and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT05895409Recruiting
Study risk factors in progressive lung scarring
This study looks at what factors contribute to worsening lung scarring seen on scans in people with certain lung diseases. Results may help doctors better understand and predict who will worsen over time.
Jinan, ShandongAges 18–80 - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+
Hear when a new Lung Fibrosis Interstitial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung fibrosis interstitial?
- Yes. Clin2 currently lists 80 recruiting lung fibrosis interstitial studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung fibrosis interstitial trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung fibrosis interstitial trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.